The endocrine therapy that blocks estrogen signaling, either by suppressing ER-α activity or by inhibiting estrogen production, is central to the multidisciplinary management of patients with breast cancer, based not only on the significant effectiveness but also on the convenience and safety of these agents6,7. The gene discussed is ESR1; the disease is breast carcinoma.